{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:32:21Z","timestamp":1785367941848,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jns.2020.117293","type":"journal-article","created":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T17:20:15Z","timestamp":1608916815000},"page":"117293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Disease course and treatment patterns in progressive supranuclear palsy: A real-world study"],"prefix":"10.1016","volume":"421","author":[{"given":"John C.","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Mellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisha J.","family":"Golden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Zamudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis A.","family":"Chiodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2020.117293_bb0005","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11940-016-0422-5","article-title":"Progressive supranuclear palsy and corticosbasal degeneration: pathophysiology and treatment options","volume":"18","author":"Lamb","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.jns.2020.117293_bb0010","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/WCO.0b013e32833be924","article-title":"Neuropathology of variants of progressive supranuclear palsy","volume":"23","author":"Dickson","year":"2010","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jns.2020.117293_bb0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/s-0034-1381736","article-title":"Progressive supranuclear palsy","volume":"34","author":"Golbe","year":"2014","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.jns.2020.117293_bb0020","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0000000000002638","article-title":"Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes","volume":"86","author":"Coyle-Gilchrist","year":"2016","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2020.117293_bb0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.parkreldis.2018.03.030","article-title":"Descriptive epidemiology of parkinsonism in the Canton of Geneva, Switzerland","volume":"54","author":"Fleury","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2020.117293_bb0030","doi-asserted-by":"crossref","first-page":"e00557","DOI":"10.1002\/brb3.557","article-title":"Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade","volume":"6","author":"Takigawa","year":"2016","journal-title":"Brain Behav."},{"key":"10.1016\/j.jns.2020.117293_bb0035","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1001\/jamaneurol.2013.114","article-title":"Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism","volume":"70","author":"Savica","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2020.117293_bb0040","first-page":"4247","article-title":"Clinical features and disability milestones in multiple system atrophy and progressive supranuclear palsy","volume":"5","author":"Lee","year":"2012","journal-title":"J Mov Disord."},{"key":"10.1016\/j.jns.2020.117293_bb0045","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/archneur.1964.00460160003001","article-title":"Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia","volume":"10","author":"Steele","year":"1964","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2020.117293_bb0050","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","article-title":"Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches","volume":"16","author":"Boxer","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2020.117293_bb0055","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(09)70042-0","article-title":"Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges","volume":"8","author":"Williams","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2020.117293_bb0060","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2020.117293_bb0065","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/jnnp.60.6.615","article-title":"Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study","volume":"60","author":"Litvan","year":"1996","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2020.117293_bb0070","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00415-015-7990-2","article-title":"Progressive supranuclear palsy: progression and survival","volume":"263","author":"Arena","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2020.117293_bb0075","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/mds.27786","article-title":"The genetic and clinico-pathological profile of early-onset progressive supranuclear palsy","volume":"34","author":"Jabbari","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2020.117293_bb0080","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1212\/01.wnl.0000338701.59007.ee","article-title":"Early diagnosis of progressive supranuclear palsy: bucking the odds","volume":"71","author":"Golbe","year":"2008","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2020.117293_bb0085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.14802\/jmd.19015","article-title":"Clinical milestones preceding the diagnosis of multiple system atrophy and progressive Supranuclear palsy: a retrospective cohort study","volume":"12","author":"Wiblin","year":"2019","journal-title":"J Mov Disord."},{"key":"10.1016\/j.jns.2020.117293_bb0090","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/mdc3.12678","article-title":"Is the ## supranuclear palsy onset to diagnosis improving?","volume":"5","author":"Mamarabadi","year":"2018","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.jns.2020.117293_bb0095","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/1531-8257(199911)14:6<947::AID-MDS1006>3.0.CO;2-O","article-title":"Progression of falls in postmortem-confirmed parkinsonian disorders","volume":"14","author":"Wenning","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2020.117293_bb0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.14802\/jmd.12010","article-title":"Clinical features and disability milestones in multiple system atrophy and progressive supranuclear palsy","volume":"5","author":"Lee","year":"2012","journal-title":"J Mov Disord."},{"key":"10.1016\/j.jns.2020.117293_bb0105","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/mds.25843","article-title":"Rate of decline in progressive supranuclear palsy","volume":"29","author":"Litvan","year":"2014","journal-title":"Mov. Disord."},{"issue":"Suppl. 3","key":"10.1016\/j.jns.2020.117293_bb0110","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1016\/S1353-8020(08)70028-2","article-title":"Unraveling progressive supranuclear palsy: from the bedside back to the bench","volume":"13","author":"Houghton","year":"2007","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2020.117293_bb0115","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1136\/jnnp-2013-305740","article-title":"Fifty years of progressive supranuclear palsy","volume":"85","author":"Colosimo","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2020.117293_bb0120","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/dme.12047","article-title":"External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?","volume":"30","author":"Saunders","year":"2013","journal-title":"Diabet. Med."},{"key":"10.1016\/j.jns.2020.117293_bb0125","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jns.2020.117293_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010352","article-title":"Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme","volume":"6","author":"Babineaux","year":"2016","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.jns.2020.117293_bb0135","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015","author":"Higgins","year":"2016","journal-title":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy"},{"key":"10.1016\/j.jns.2020.117293_bb0140","author":"European Pharmaceutical Market Research Association"},{"key":"10.1016\/j.jns.2020.117293_bb0145","author":"US Department of Health and Human Services"},{"key":"10.1016\/j.jns.2020.117293_bb0150","author":"Health Information Technology"},{"key":"10.1016\/j.jns.2020.117293_bb0155","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/brain\/awn065","article-title":"Clinical outcomes of progressive supranuclear palsy and multiple system atrophy","volume":"131","author":"O\u2019Sullivan","year":"2008","journal-title":"Brain."},{"key":"10.1016\/j.jns.2020.117293_bb0160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.14802\/jmd.15060","article-title":"Clinical approach to progressive Supranuclear palsy","volume":"9","author":"Ling","year":"2016","journal-title":"J Mov Disord."},{"key":"10.1016\/j.jns.2020.117293_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","article-title":"Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop","volume":"47","author":"Litvan","year":"1996","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2020.117293_bb0170","doi-asserted-by":"crossref","first-page":"15007","DOI":"10.1038\/npjparkd.2015.7","article-title":"Comparison of clinical features in pathologically confirmed PSP and MSA patients followed at a tertiary center","volume":"1","author":"Xie","year":"2015","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.jns.2020.117293_bb0175","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.parkreldis.2016.03.015","article-title":"Tremor in progressive supranuclear palsy","volume":"27","author":"Fujioka","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2020.117293_bb0180","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/WNF.0b013e31826e3406","article-title":"Amantadine for freezing of gait in patients with Parkinson\u2019s disease","volume":"35","author":"Malkani","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2020.117293_bb0185","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11940-012-0168-7","article-title":"Treatment options for tauopathies","volume":"14","author":"Karakaya","year":"2012","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.jns.2020.117293_bb0190","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/mds.22794","article-title":"A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy","volume":"25","author":"Schrag","year":"2010","journal-title":"Mov. Disord."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20306298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20306298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:52:02Z","timestamp":1758383522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X20306298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":38,"alternative-id":["S0022510X20306298"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2020.117293","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease course and treatment patterns in progressive supranuclear palsy: A real-world study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2020.117293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117293"}}